Loading…
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $228M | $53M | $31M | $42M | 23.9% | -0.9% | 2.8% |
| 2024 | $230M | $48M | $30M | $39M | 32.9% | -2.2% | 40.2% |
| 2023 | $236M | $48M | $22M | $14M | 40.4% | 3.3% | 1079450.0% |
| 2022 | $228M | $22M | $0M | $-23M | 0.0% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 228.03 | 235.64 | 230.47 | 228.37 |
| Cost Of Revenue | 55.09 | 62.68 | 64.40 | 58.16 |
| Gross Profit | 172.94 | 172.96 | 166.06 | 170.21 |
| Operating Expense | 142.22 | 140.31 | 135.10 | 132.91 |
| Operating Income | 30.72 | 32.64 | 30.97 | 37.30 |
| EBITDA | 21.89 | 47.52 | 48.08 | 53.34 |
| EBIT | 12.05 | 36 | 36.55 | 42.40 |
| Pretax Income | 0.46 | 22.67 | 24.10 | 35.78 |
| Tax Provision | 0.46 | 1.08 | -6.18 | 4.67 |
| Net Income | 0 | 21.59 | 30.28 | 31.11 |
| Net Income Common Stockholders | 0 | 21.59 | 30.28 | 31.11 |
| Total Expenses | 197.31 | 203 | 199.50 | 191.07 |
| Interest Expense | 11.59 | 13.33 | 12.45 | 6.62 |
| Interest Income | 0.81 | 2.60 | 4.72 | 4.08 |
| Research And Development | 52.24 | 50.38 | 54.94 | 62.07 |
| Selling General And Administration | 89.98 | 89.93 | 80.68 | 71.21 |
| Normalized EBITDA | 41.34 | 47.52 | 48.08 | 53.34 |
| Normalized Income | 15.37 | 21.59 | 30.28 | 31.11 |
| Basic EPS | 0 | 0.46 | 0.62 | 0.62 |
| Diluted EPS | 0 | 0.45 | 0.62 | 0.61 |
| Tax Effect Of Unusual Items | -4.09 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0.21 | 0.05 | 0.21 | 0.13 |
| Total Unusual Items | -19.46 | -0.62 | 0 | 0 |
| Total Unusual Items Excluding Goodwill | -19.46 | -0.62 | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | 0 | 21.59 | 30.28 | 31.11 |
| Reconciled Depreciation | 9.84 | 11.52 | 11.52 | 10.94 |
| Reconciled Cost Of Revenue | 55.09 | 62.68 | 64.40 | 58.16 |
| Net Interest Income | -10.78 | -10.72 | -7.73 | -2.54 |
| Net Income From Continuing And Discontinued Operation | 0 | 21.59 | 30.28 | 31.11 |
| Total Operating Income As Reported | 23.72 | 32.64 | 30.97 | 37.30 |
| Diluted Average Shares | 44.93 | 47.55 | 49.10 | 50.65 |
| Basic Average Shares | 44.67 | 47.13 | 48.65 | 50.01 |
| Diluted NI Availto Com Stockholders | 0 | 21.59 | 30.28 | 31.11 |
| Net Income Including Noncontrolling Interests | 0 | 21.59 | 30.28 | 31.11 |
| Net Income Continuous Operations | 0 | 21.59 | 30.28 | 31.11 |
| Other Income Expense | -19.48 | 0.76 | 0.86 | 1.03 |
| Other Non Operating Income Expenses | -0.03 | 0.76 | 0.86 | 1.03 |
| Special Income Charges | -19.46 | -0.62 | 0 | 0 |
| Other Special Charges | 19.46 | 0 | 0 | 0 |
| Write Off | 0 | 0.62 | 0 | 0 |
| Restructuring And Mergern Acquisition | 7 | 0 | 0 | 0 |
| Net Non Operating Interest Income Expense | -10.78 | -10.72 | -7.73 | -2.54 |
| Interest Expense Non Operating | 11.59 | 13.33 | 12.45 | 6.62 |
| Interest Income Non Operating | 0.81 | 2.60 | 4.72 | 4.08 |
| Provision For Doubtful Accounts | 0 | 0.88 | -0.52 | -0.36 |
| General And Administrative Expense | 89.98 | 88.43 | 80.68 | 71.21 |
| Other Gand A | 52 | 48.08 | 43.56 | 32.26 |
| Salaries And Wages | 37.98 | 40.34 | 37.12 | 38.95 |
| Operating Revenue | 228.03 | 235.64 | 230.47 | 228.37 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Puma Biotechnology, Inc.this co. | PBYI | $381M | 12.26↓ discount | 2.89 | 23.9% | 6.57 |
| TruBridge, Inc. | TBRG | $386M | 88.72 | 2.10 | 2.4% | 13.37 |
| Weave Communications, Inc. | WEAV | $385M | - | 4.61 | -34.1% | -18.58 |
| Cerus Corporation | CERS | $385M | - | 5.75 | -24.1% | -52.90 |
| Niagen Bioscience, Inc. | NAGE | $381M |
| 23.80 |
| 4.97 |
| 22.7% |
| 21.23 |
| Viemed Healthcare, Inc. | VMD | $381M | 26.73 | 2.66 | 10.4% | 7.66 |
| Rocket Pharmaceuticals, Inc. | RCKT | $380M | - | 1.36 | -80.5% | -0.98 |
| OrthoPediatrics Corp. | KIDS | $376M | - | 1.06 | -11.4% | -53.45 |
| NRC Health | NRC | $373M | 42.41 | 26.76 | 82.9% | 12.41 |
| Peer Median | - | 34.57 | 3.63 | -4.5% | 3.34 | |